Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARGX 
argenx NV ADR (ARGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARGX (3-star) is a STRONG-BUY. BUY since 25 days. Profits (18.93%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $806.19
1 Year Target Price $806.19
| 14 | Strong Buy |
| 7 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.8% | Avg. Invested days 52 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 43.33B USD | Price to earnings Ratio 35.97 | 1Y Target Price 806.19 |
Price to earnings Ratio 35.97 | 1Y Target Price 806.19 | ||
Volume (30-day avg) 22 | Beta -0.01 | 52 Weeks Range 510.06 - 710.00 | Updated Date 08/28/2025 |
52 Weeks Range 510.06 - 710.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 19.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 41.03% | Operating Margin (TTM) 21.08% |
Management Effectiveness
Return on Assets (TTM) 4.83% | Return on Equity (TTM) 24.72% |
Valuation
Trailing PE 35.97 | Forward PE 47.39 | Enterprise Value 38661650924 | Price to Sales(TTM) 13.88 |
Enterprise Value 38661650924 | Price to Sales(TTM) 13.88 | ||
Enterprise Value to Revenue 12.66 | Enterprise Value to EBITDA 56.06 | Shares Outstanding 61199900 | Shares Floating 61134446 |
Shares Outstanding 61199900 | Shares Floating 61134446 | ||
Percent Insiders - | Percent Institutions 53.3 |
Upturn AI SWOT
argenx NV ADR
Company Overview
History and Background
argenx NV ADR was founded in 2008 in the Netherlands. Initially focused on antibody discovery, it has evolved into a global immunology company with a commercialized product and a robust pipeline.
Core Business Areas
- Immunology: argenx focuses on developing antibody-based therapies for severe autoimmune diseases and cancer.
- Therapeutic Antibody Discovery: The company leverages its Innovative Simple Antibody platform to generate differentiated antibody candidates.
Leadership and Structure
argenx is led by CEO Tim Van Hauwermeiren. The company operates with a functional organizational structure, emphasizing research, development, and commercialization.
Top Products and Market Share
Key Offerings
- VYVGART (efgartigimod): VYVGART is a human IgG1 Fc receptor blocker approved for the treatment of generalized myasthenia gravis (gMG). Revenue for VYVGART in 2023 was $1.2B+. Competitors include Alexion (Soliris, Ultomiris) and Immunovant (Batamoclatam).
Market Dynamics
Industry Overview
The immunology market is experiencing significant growth driven by the increasing prevalence of autoimmune diseases and advancements in antibody-based therapies.
Positioning
argenx is a key player in the immunology market with a focus on innovative antibody therapies. Its competitive advantage lies in its differentiated technology platform and its first-to-market advantage with VYVGART.
Total Addressable Market (TAM)
The TAM for autoimmune disease treatments is estimated to be in the tens of billions of dollars. argenx is well-positioned to capture a significant share of this market with its expanding pipeline and approved therapies.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- First-to-market advantage with VYVGART
- Strong financial position
- Experienced management team
- Broad pipeline of antibody therapies
Weaknesses
- Reliance on a single commercialized product
- High R&D expenses
- Competition from established pharmaceutical companies
- Regulatory risks
Opportunities
- Expansion of VYVGART into new indications
- Advancement of pipeline candidates
- Strategic partnerships and acquisitions
- Increasing prevalence of autoimmune diseases
Threats
- Competition from biosimilars
- Unsuccessful clinical trials
- Adverse regulatory decisions
- Economic downturn
Competitors and Market Share
Key Competitors
- ALXN
- IMVT
Competitive Landscape
argenx has a strong competitive position with VYVGART, but faces competition from established pharmaceutical companies and emerging competitors.
Growth Trajectory and Initiatives
Historical Growth: argenx has experienced rapid growth in recent years due to the commercialization of VYVGART.
Future Projections: Analysts project continued growth in revenue and earnings as argenx expands the indications for VYVGART and advances its pipeline.
Recent Initiatives: argenx is actively expanding its commercial infrastructure and investing in R&D to support future growth.
Summary
argenx is a growing biopharmaceutical company with a focus on immunology. VYVGART's commercial success has fueled rapid revenue growth. The company is investing heavily in R&D to expand its pipeline and solidify its market position. Competition and regulatory hurdles pose potential challenges to future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is an approximation based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About argenx NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-05-18 | Co-Founder, CEO & Executive Director Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1599 | Website https://argenx.com |
Full time employees 1599 | Website https://argenx.com | ||
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.